Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer

作者
Kaori Hino,Tomohiro Nishina,Takeshi Kajiwara,Hideaki Bando,Maho Nakamura,Shigenori Kadowaki,Keiko Minashi,Satoshi Yuki,Takashi Ohta,Hiroki Hara,Takuro Mizukami,Toshikazu Moriwaki,Koushiro Ohtsubo,Masato Komoda,Seiichiro Mitani,Fumio Nagashima,Ken Kato,Takanobu Yamada,Hiroko Hasegawa,Kentaro Yamazaki,Takayuki Yoshino,Ichinosuke Hyodo
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号: (6)
标识
DOI:10.1200/po.22.00135
摘要

PURPOSE ERBB2 copy number (CN), measured using next-generation sequencing, is a predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 (HER2)–positive advanced esophagogastric and gastric cancer (AGC). We aimed to investigate the association of ERBB2 amplification and gene coalterations with response and resistance to trastuzumab-combined chemotherapy. METHODS The SCRUM-Japan GI-SCREEN was a comprehensive genomic profiling project of GI cancer tissues using Oncomine Cancer Research Panel and Oncomine Comprehensive Assay. From 885 patients with AGC who successfully underwent gene profiling, 74 with ERBB2 amplification (CN ≥ 4.0) and who received first-line trastuzumab-combined chemotherapy were selected, and ERBB2 CN and gene coalterations were assessed. RESULTS ERBB2 CN did not differ in tumor response to trastuzumab-combined chemotherapy (one-way analysis of variance test, P = .37). Multivariate analysis using the Cox proportional hazard model revealed that ERBB2 CN (continuous log 2 -converted CN, hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P < .01) and receptor/oncogene amplifications in the HER2 signaling pathway (hazard ratio, 2.5; 95% CI, 1.2 to 5.3; P = .01) were significant predictors for progression-free survival (PFS). ERBB2 variants coexisted in five patients (7%) and were missense mutations. Two patients with low variant allele frequencies (VAFs; 8%, 12%) showed high ERBB2 CN (55, 80) and durable response (≥ 20 months), whereas three patients with high VAFs (66%–90%) showed low ERBB2 CN (8-11) and no response with short PFS (1-10 months). CONCLUSION ERBB2 CN and gene coamplification in the HER2 signaling pathway were positive and negative predictors of PFS in trastuzumab-treated HER2-positive AGC patients, respectively. HER2-positive AGC patients with a high VAF of ERBB2 showed poor outcomes and may need HER2 tyrosine kinase inhibitors and trastuzumab deruxtecan.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淳于安筠发布了新的文献求助30
2秒前
柳叶洋完成签到,获得积分10
2秒前
下一秒发布了新的文献求助10
5秒前
6秒前
7秒前
无花果应助科研通管家采纳,获得10
7秒前
Akim应助科研通管家采纳,获得10
7秒前
852应助科研通管家采纳,获得10
7秒前
SYLH应助科研通管家采纳,获得30
7秒前
斯文败类应助科研通管家采纳,获得10
7秒前
Owen应助科研通管家采纳,获得10
7秒前
orixero应助科研通管家采纳,获得10
7秒前
Orange应助科研通管家采纳,获得10
7秒前
情怀应助科研通管家采纳,获得30
7秒前
Jasper应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
8秒前
Ava应助科研通管家采纳,获得10
8秒前
情怀应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
8秒前
8秒前
SYLH应助shensiang采纳,获得20
9秒前
专一的从波完成签到 ,获得积分10
9秒前
领导范儿应助msjs采纳,获得30
9秒前
量子星尘发布了新的文献求助10
11秒前
安静的幼旋完成签到,获得积分10
12秒前
12秒前
白石溪发布了新的文献求助10
12秒前
12秒前
loski发布了新的文献求助10
12秒前
14秒前
勤恳化蛹完成签到,获得积分10
14秒前
黄健斌发布了新的文献求助10
15秒前
16秒前
人生如梦应助2311采纳,获得10
17秒前
l璐w璐l完成签到,获得积分10
18秒前
ZY发布了新的文献求助10
19秒前
l璐w璐l发布了新的文献求助10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174